"Last year we generated more data in three months than in our entire 300-year history. With the Cerebras CS-1, we have been able to increase the complexity of the encoder models that we can generate, while decreasing their training time by 80x."

Kim Branson

SVP Global Head of AI and ML @ GlaxoSmithKline

See how GlaxoSmithKline is using the Cerebras System

GlaxoSmithKline and Cerebras are Advancing the State of the Art in AI for Drug Discovery

GSK published findings: EBERT models for epigonomic research were 160 times faster on the CS-1 than on a GPU

How AI Is Aiming at the Bad Math of Drug Development

Unconventional collaborations between biopharma and tech are starting to take off

Unconventional collaborations between biopharma and tech are starting to take off